Brian Feagan
Appearances
- DateMay 8, 2023This session presents the best submitted clinical abstracts as determined by their specific council sections…
- DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
- DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
- DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Speakers
Icahn School of Medicine, Mount SinaiSwedish Medical CenterKatholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven - DateMay 7, 2023BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…
Speakers
Presenter
- DateMay 7, 2023Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Presenter
Speakers
University of Chicago Division of the Biological SciencesCedars-Sinai Medical Center - DateMay 9, 2023BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…
Presenter
Brigham and Women's HospitalSpeakers
University of PennsylvaniaUniversity of Chicago Division of the Biological Sciences - DateMay 20, 2024The Phase 3 QUASAR Maintenance Study (NCT04033445) is a randomized-withdrawal, double-blind, placebo(PBO)-controlled, study that evaluated the efficacy and safety of maintenance treatment with subcutaneous (SC) guselkumab (GUS), an IL-23p19 subunit antagonist, in patients (pts) with moderately to s…
Presenter
University of Chicago Division of the Biological SciencesSpeakers
- DateMay 21, 2024BACKGROUND: Eosinophil infiltration is a hallmark of eosinophilic esophagitis (EoE). Histologic assessment of esophageal biopsies is required for diagnosis and evaluation of treatment effect. Current diagnostic criteria are based mainly upon a peak eosinophil count (PEC) ≥15…
Presenter
Speakers
Amsterdam UMC, University of AmsterdamUniversity of North Carolina School of Medicine - DateMay 20, 2024BACKGROUND: Disease clearance in ulcerative colitis (UC) is defined as concurrent achievement of clinical, endoscopic, and histologic remission…
Presenter
Speakers
Icahn School of Medicine at Mount SinaiKatholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven - DateMay 18, 2024Although the cause of Crohn’s disease (CD) is unknown, recent studies have identified a number of biomarkers associated with the risk of developing CD in healthy at-risk individuals…
Presenter
Speakers
Tel Aviv Sourasky Medical CenterSinai Health SystemUniversity of ManitobaMcMaster University
